Monograph Details
|
|
Endocrine System
> Hypogonadism
|
|
OXANDRIN |
| Manufacturer |
|
Savient Pharmaceuticals |
| Legal Classification |
|
CIII |
| Pharmacological Class |
|
Androgen. |
| Generic Name |
|
Oxandrolone 2.5mg+, 10mg; tabs (+scored). |
| Indications |
|
As an adjunct to promote weight gain after extensive surgery, chronic infections, severe trauma, and without definite cause, to offset protein catabolism associated with prolonged corticosteroid administration, and for relief of osteoporotic bone pain. |
| Contraindications |
|
Male breast or prostate carcinoma. Nephrosis. Hypercalemia. Pregnancy (Cat.X). |
| Precautions |
|
Discontinue if jaundice, abnormal liver function, hypercalcemia, or edema occurs. Cardiac, hepatic, or renal dysfunction. Monitor hepatic function, blood, and bone age. Elderly. Young children. Nursing mothers: not recommended. |
| Interactions |
|
May potentiate oral anticoagulants, oxyphenbutazone. May alter insulin needs. Increased risk of edema with ACTH, corticosteroids. |
| Adverse Reactions |
|
Peliosis hepatis, premature epiphyseal closure in adolescents, edema, hepatic carcinoma, prostatic hypertrophy or carcinoma, gynecomastia, priapism, oligospermia, nausea, jaundice, hirsutism, virilization, male pattern baldness, acne, polycythemia, headache, anxiety, depression, paresthesias, altered libido, fluid and electrolyte disturbances, suppression of clotting factors, increased serum cholesterol. |
| How Supplied |
Tabs 2.5mg—100
10mg—60 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
